{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Hoosier+Cancer+Research+Network", "query": { "sponsor": "Hoosier Cancer Research Network", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Hoosier+Cancer+Research+Network&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Hoosier+Cancer+Research+Network&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T14:25:48.387Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00379912", "title": "Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Erythropoietin", "type": "DRUG" }, { "name": "Azacitidine (Monotherapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Larry Cripe, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2006-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 9, "location_summary": "Galesburg, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 4 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379912" }, { "nct_id": "NCT02382406", "title": "Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "MK-3475 (Phase I)", "type": "DRUG" }, { "name": "MK-3475 (Phase II)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nisha Mohindra, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2015-06-04", "completion_date": "2022-04-14", "has_results": true, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 5, "location_summary": "Duarte, California • Chicago, Illinois • Indianapolis, Indiana + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02382406" }, { "nct_id": "NCT03913455", "title": "Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Guadecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shadia Jalal, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-06-06", "completion_date": "2022-02-02", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Muncie, Indiana • Charlottesville, Virginia + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Muncie", "state": "Indiana" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03913455" }, { "nct_id": "NCT03272217", "title": "Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arjun Balar, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-09-13", "completion_date": "2022-03-17", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Chicago, Illinois • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03272217" }, { "nct_id": "NCT07479979", "title": "Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" }, { "name": "Isatuximab SC Wearable Injection System", "type": "DEVICE" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Natalie Callander", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2026-05-21", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07479979" }, { "nct_id": "NCT05442216", "title": "Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Tagraxofusp", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joshua Zeidner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2024-05-01", "completion_date": "2031-07-21", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 7, "location_summary": "Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05442216" }, { "nct_id": "NCT03840967", "title": "A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shadia Jalal, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-07-09", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 4, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840967" }, { "nct_id": "NCT03547999", "title": "A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "MVA-BN-CV301", "type": "BIOLOGICAL" }, { "name": "FPV-CV301", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Patrick Boland", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-06-26", "completion_date": "2024-03-13", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 7, "location_summary": "Duarte, California • Miami, Florida • Westwood, Kansas + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547999" }, { "nct_id": "NCT03476174", "title": "Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ralph Hauke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-05-07", "completion_date": "2019-10-16", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03476174" }, { "nct_id": "NCT05852717", "title": "Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large Cell Lymphoma, Diffuse", "Relapsed Cancer", "Refractory Cancer" ], "interventions": [ { "name": "AutoSCT OR CAR T-cell Therapy", "type": "PROCEDURE" }, { "name": "GDP", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Dipenkumar Modi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-10-31", "completion_date": "2028-11-24", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-04T14:25:48.387Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05852717" } ] }